ASX Penny Stocks With Market Caps At Least A$100M

The Australian stock market is experiencing a cautious phase, with the ASX extending its losses amid concerns over unlikely rate cuts and recent inflation data influencing the Reserve Bank's decisions. In such a climate, investors may turn their attention to penny stocks—often seen as smaller or newer companies that offer growth opportunities at lower price points. Despite being considered an outdated term, penny stocks remain relevant for those seeking potential upside when backed by strong financial health.

Top 10 Penny Stocks In Australia

Name	Share Price	Market Cap	Financial Health Rating
LaserBond (ASX:LBL)	A$0.615	A$72.09M	★★★★★★
Embark Early Education (ASX:EVO)	A$0.785	A$144.03M	★★★★☆☆
MaxiPARTS (ASX:MXI)	A$1.895	A$104.82M	★★★★★★
Helloworld Travel (ASX:HLO)	A$1.745	A$281.08M	★★★★★★
Austin Engineering (ASX:ANG)	A$0.52	A$322.48M	★★★★★☆
Navigator Global Investments (ASX:NGI)	A$1.69	A$828.23M	★★★★★☆
Perenti (ASX:PRN)	A$1.17	A$1.08B	★★★★★★
Atlas Pearls (ASX:ATP)	A$0.145	A$63.17M	★★★★★★
GTN (ASX:GTN)	A$0.465	A$91.13M	★★★★★★
Joyce (ASX:JYC)	A$4.22	A$124.48M	★★★★★★

Click here to see the full list of 1,033 stocks from our ASX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Joyce (ASX:JYC)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Joyce Corporation Ltd (ASX:JYC) is an Australian company that retails kitchen and wardrobe products, with a market cap of A$124.48 million.

Operations: The company's revenue is derived from three segments: Retail Bedding - Franchise Operation (A$5.89 million), Retail Bedding Stores - Company-owned (A$17.26 million), and Retail Kitchen and Wardrobe Showrooms (A$121.30 million).

Market Cap: A$124.48M

Joyce Corporation Ltd, with a market cap of A$124.48 million, shows promise in the penny stock arena due to its diversified revenue streams across retail bedding and kitchen products. The company has demonstrated high-quality earnings, with a significant 27.7% annual profit growth over the past five years and an outstanding return on equity of 45.2%. Despite shareholder dilution over the past year, Joyce remains debt-free with stable weekly volatility. Recent financials highlight marginal sales growth to A$145.51 million and improved net income to A$8.86 million for the year ended June 30, 2024, alongside a confirmed dividend payout strategy.

• Take a closer look at Joyce's potential here in our financial health report.
• Learn about Joyce's historical performance here.

K&S (ASX:KSC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: K&S Corporation Limited operates in the transportation and logistics, warehousing, and fuel distribution sectors across Australia and New Zealand, with a market cap of A$476.23 million.

Operations: The company's revenue is primarily derived from its Australian Transport segment at A$582.80 million, followed by Fuel distribution at A$230.79 million and New Zealand Transport operations contributing A$72.93 million.

Market Cap: A$476.23M

K&S Corporation Limited, with a market cap of A$476.23 million, offers potential within the penny stock landscape through its diverse operations in transportation and logistics. The company reported revenues of A$834.03 million for the year ending June 30, 2024, with net income rising to A$31.23 million. Despite a modest earnings growth of 9.1% over the past year compared to its five-year average, K&S maintains high-quality earnings and stable weekly volatility at 5%. However, challenges include an increased debt-to-equity ratio over five years and short-term assets not fully covering long-term liabilities.

• Click to explore a detailed breakdown of our findings in K&S' financial health report.
• Gain insights into K&S' historical outcomes by reviewing our past performance report.

Race Oncology (ASX:RAC)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Race Oncology Limited, with a market cap of A$255.64 million, is a clinical stage biopharmaceutical company dedicated to addressing the unmet needs of cancer patients through less damaging treatments.

Operations: The company generates its revenue primarily from Australia, amounting to A$4.00 million.

Market Cap: A$255.64M

Race Oncology Limited, with a market cap of A$255.64 million, remains a speculative option in the penny stock realm due to its pre-revenue status and ongoing unprofitability. The company reported a net loss of A$13.82 million for the fiscal year ending June 2024, reflecting increased losses over five years at an annual rate of 27.6%. Despite these challenges, Race maintains a debt-free position and has sufficient short-term assets (A$17.4M) to cover liabilities, alongside a cash runway exceeding one year if current free cash flow trends persist. Recent board changes may influence strategic direction moving forward.

• Navigate through the intricacies of Race Oncology with our comprehensive balance sheet health report here.
• Evaluate Race Oncology's prospects by accessing our earnings growth report.

Summing It All Up

• Discover the full array of 1,033 ASX Penny Stocks right here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com